Apollo Global Management's (APO) Novolex has agreed to buy Pactiv Evergreen (PTVE) for $18 per share in an all-cash deal valued at $6.70 billion, the companies said Monday.
Following deal closure expected in mid-2025, Pactiv Evergreen shares will no longer be listed on the Nasdaq and the combined company will be led by Novolex CEO and Chairman Stan Bikulege, the companies said.